Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 14, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting held on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 675,000 Ordinary shares of 25 pence each.
- Purchase Date: June 14, 2006.
- Price Per Share: 1,475.9598 pence.
- Treasury Holdings Post-Purchase: 172,901,678 shares.
- Shares in Issue (Excluding Treasury): 5,809,625,703 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 675,000 shares to be held in Treasury, increasing its total Treasury holdings to approximately 172.9 million shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 675,000 share repurchase based on the disclosed price of 1,475.9598 pence per share.
- Confirm the updated total share count (5,809,625,703 in issue) against subsequent filings to ensure accuracy.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authorization.